Today's Analyst Stock Ratings | Upgrades, Downgrades

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD83,901.53+0.27%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

							Get Alert
Oct 7, 2026	BNTXBioNTech	$97.20	17.28%	Terence FlynnMorgan Stanley 72%	114 115	Previous Overweight Current Overweight	Get Alert
Sep 8, 2026	BNTXBioNTech	$97.20	8.02%	Evan SeigermanBMO Capital 72%	105 128	Previous Outperform Current Market Perform	Get Alert
Aug 31, 2026	BNTXBioNTech	$97.20	39.92%	John NewmanCanaccord Genuity 41%	136 142	Previous Buy Current Buy	Get Alert
Aug 5, 2026	BNTXBioNTech	$97.20	28.6%	Geoff MeachamCitigroup 75%	125 130	Previous Buy Current Buy	Get Alert
Aug 5, 2026	BNTXBioNTech	$97.20	33.74%	Cory KasimovEvercore ISI Group 67%	130 135	Previous Outperform Current Outperform	Get Alert
Jul 8, 2026	BNTXBioNTech	$97.20	22.43%	Terence FlynnMorgan Stanley 72%	119 126	Previous Overweight Current Overweight	Get Alert
May 27, 2026	BNTXBioNTech	$97.20	38.89%	David DaiUBS 52%	117 135	Previous Neutral Current Buy	Get Alert
May 22, 2026	BNTXBioNTech	$97.20	-1.23%	Jeffrey WalchBernstein 13%	96	Previous Initiates Current Market Perform	Get Alert
May 6, 2026	BNTXBioNTech	$97.20	62.55%	John NewmanCanaccord Genuity 41%	158 171	Previous Buy Current Buy	Get Alert
May 6, 2026	BNTXBioNTech	$97.20	44.03%	Mohit BansalWells Fargo 71%	140 150	Previous Overweight Current Overweight	Get Alert
Apr 27, 2026	BNTXBioNTech	$97.20	33.74%	Robert BurnsHC Wainwright & Co. 64%	130 130	Previous Buy Current Buy	Get Alert
Apr 10, 2026	BNTXBioNTech	$97.20	29.63%	Terence FlynnMorgan Stanley 72%	125 126	Previous Overweight Current Overweight	Get Alert
Mar 31, 2026	BNTXBioNTech	$97.20	33.74%	Robert BurnsHC Wainwright & Co. 64%	130 140	Previous Buy Current Buy	Get Alert
Mar 11, 2026	BNTXBioNTech	$97.20	28.6%	Terence FlynnMorgan Stanley 72%	125 134	Previous Overweight Current Overweight	Get Alert
Mar 11, 2026	BNTXBioNTech	$97.20	75.93%	John NewmanCanaccord Genuity 41%	171 171	Previous Buy Current Buy	Get Alert
Mar 11, 2026	BNTXBioNTech	$97.20	33.74%	Geoff MeachamCitigroup 75%	130 145	Previous Buy Current Buy	Get Alert
Mar 11, 2026	BNTXBioNTech	$97.20	-3.29%	Yaron WerberTD Cowen 50%	94 116	Previous Hold Current Hold	Get Alert
Mar 11, 2026	BNTXBioNTech	$97.20	31.69%	Etzer DaroutBMO Capital 68%	128 143	Previous Outperform Current Outperform	Get Alert
Mar 10, 2026	BNTXBioNTech	$97.20	41.98%	Akash TewariJefferies 49%	138 151	Previous Buy Current Buy	Get Alert
Jan 16, 2026	BNTXBioNTech	$97.20	46.09%	Asad Haider Goldman Sachs 66%	115 142	Previous Neutral Current Buy	Get Alert
Nov 10, 2025	BNTXBioNTech	$97.20	44.03%	Robert BurnsHC Wainwright & Co. 64%	136 140	Previous Buy Current Buy	Get Alert
Nov 6, 2025	BNTXBioNTech	$97.20	20.37%	David DaiUBS 52%	115 117	Previous Neutral Current Neutral	Get Alert
Oct 23, 2025	BNTXBioNTech	$97.20	23.46%	Jessica FyeJP Morgan 65%	120 121	Previous Neutral Current Neutral	Get Alert
Oct 10, 2025	BNTXBioNTech	$97.20	34.77%	Terence FlynnMorgan Stanley 72%	131 133	Previous Overweight Current Overweight	Get Alert
Sep 22, 2025	BNTXBioNTech	$97.20	24.49%	Jessica FyeJP Morgan 65%	116 121	Previous Neutral Current Neutral	Get Alert
Sep 8, 2025	BNTXBioNTech	$97.20	39.92%	Robert BurnsHC Wainwright & Co. 64%	136 136	Previous Buy Current Buy	Get Alert
Aug 14, 2025	BNTXBioNTech	$97.20	39.92%	Robert BurnsHC Wainwright & Co. 64%	136 138	Previous Buy Current Buy	Get Alert
Aug 5, 2025	BNTXBioNTech	$97.20	54.32%	Mohit BansalWells Fargo 71%	150 170	Previous Overweight Current Overweight	Get Alert
Aug 5, 2025	BNTXBioNTech	$97.20	37.86%	Tazeen AhmadB of A Securities 57%	126 134	Previous Buy Current Buy	Get Alert
Jul 16, 2025	BNTXBioNTech	$97.20	29.63%	Tazeen AhmadB of A Securities 57%	126 127	Previous Buy Current Buy	Get Alert
Jul 10, 2025	BNTXBioNTech	$97.20	36.83%	Terence FlynnMorgan Stanley 72%	132 133	Previous Overweight Current Overweight	Get Alert
Jun 25, 2025	BNTXBioNTech	$97.20	41.98%	Robert BurnsHC Wainwright & Co. 64%	138 138	Previous Buy Current Buy	Get Alert
Jun 16, 2025	BNTXBioNTech	$97.20	41.98%	Robert BurnsHC Wainwright & Co. 64%	138 145	Previous Buy Current Buy	Get Alert
Jun 5, 2025	BNTXBioNTech	$97.20	49.18%	Robert BurnsHC Wainwright & Co. 64%	134 145	Previous Buy Current Buy	Get Alert
Jun 3, 2025	BNTXBioNTech	$97.20	59.47%	Asthika GoonewardeneTruist Securities 50%	151 155	Previous Buy Current Buy	Get Alert
May 29, 2025	BNTXBioNTech	$97.20	13.17%	Asad Haider Goldman Sachs 66%	110	Previous Initiates Current Neutral	Get Alert
May 22, 2025	BNTXBioNTech	$97.20	19.34%	Jessica FyeJP Morgan 65%	116 120	Previous Neutral Current Neutral	Get Alert
May 22, 2025	BNTXBioNTech	$97.20	37.86%	Robert BurnsHC Wainwright & Co. 64%	134 134	Previous Buy Current Buy	Get Alert
May 14, 2025	BNTXBioNTech	$97.20	37.86%	Robert BurnsHC Wainwright & Co. 64%	134 145	Previous Buy Current Buy	Get Alert
May 6, 2025	BNTXBioNTech	$97.20	44.03%	Geoff MeachamCitigroup 75%	140 145	Previous Buy Current Buy	Get Alert
May 6, 2025	BNTXBioNTech	$97.20	35.8%	Terence FlynnMorgan Stanley 72%	132 140	Previous Overweight Current Overweight	Get Alert
Apr 1, 2025	BNTXBioNTech	$97.20	49.18%	Robert BurnsHC Wainwright & Co. 64%	145 150	Previous Buy Current Buy	Get Alert
Mar 13, 2025	BNTXBioNTech	$97.20	49.18%	Geoff MeachamCitigroup 75%	145	Previous Initiates Current Buy	Get Alert
Mar 11, 2025	BNTXBioNTech	$97.20	55.35%	Asthika GoonewardeneTruist Securities 50%	151 172	Previous Buy Current Buy	Get Alert
Mar 11, 2025	BNTXBioNTech	$97.20	43%	Terence FlynnMorgan Stanley 72%	139 145	Previous Overweight Current Overweight	Get Alert
Mar 11, 2025	BNTXBioNTech	$97.20	76.38%	John NewmanCanaccord Genuity 41%	171.44 171.44	Previous Buy Current Buy	Get Alert
Mar 11, 2025	BNTXBioNTech	$97.20	47.12%	Etzer DaroutBMO Capital 68%	130 143	Previous Outperform Current Outperform	Get Alert
Jan 27, 2025	BNTXBioNTech	$97.20	23.46%	Jessica FyeJP Morgan 65%	120 122	Previous Neutral Current Neutral	Get Alert
Jan 10, 2025	BNTXBioNTech	$97.20	76.95%	Asthika GoonewardeneTruist Securities 50%	172	Previous Initiates Current Buy	Get Alert
Dec 11, 2024	BNTXBioNTech	$97.20	74.9%	Mohit BansalWells Fargo 71%	170	Previous Initiates Current Overweight	Get Alert
Nov 27, 2024	BNTXBioNTech	$97.20	76.38%	William MaughanCanaccord Genuity 68%	171 171.44	Previous Buy Current Buy	Get Alert
Nov 26, 2024	BNTXBioNTech	$97.20	25.51%	Jessica FyeJP Morgan 65%	122 124	Previous Neutral Current Neutral	Get Alert
Nov 19, 2024	BNTXBioNTech	$97.20	28.6%	Cory KasimovEvercore ISI Group 67%	110 125	Previous In-Line Current Outperform	Get Alert
Nov 18, 2024	BNTXBioNTech	$97.20	75.93%	John NewmanCanaccord Genuity 41%	171 171	Previous Buy Current Buy	Get Alert
Nov 18, 2024	BNTXBioNTech	$97.20	54.32%	Robert BurnsHC Wainwright & Co. 64%	150 150	Previous Buy Current Buy	Get Alert
Nov 14, 2024	BNTXBioNTech	$97.20	75.93%	John NewmanCanaccord Genuity 41%	171 171	Previous Buy Current Buy	Get Alert
Nov 8, 2024	BNTXBioNTech	$97.20	40.95%	Chris ShibutaniGoldman Sachs 70%	90 137	Previous Neutral Current Buy	Get Alert
Nov 6, 2024	BNTXBioNTech	$97.20	25.51%	Yaron WerberTD Cowen 50%	122 132	Previous Hold Current Hold	Get Alert
Nov 5, 2024	BNTXBioNTech	$97.20	25.51%	Yaron WerberTD Cowen 50%	122 132	Previous Hold Current Hold	Get Alert
Nov 4, 2024	BNTXBioNTech	$97.20	27.57%	Jessica FyeJP Morgan 65%	124 125	Previous Neutral Current Neutral	Get Alert
Oct 7, 2024	BNTXBioNTech	$97.20	39.92%	Yifeng LiuHSBC 31%	97 136	Previous Buy Current Buy	Get Alert
Oct 7, 2024	BNTXBioNTech	$97.20	54.32%	Robert BurnsHC Wainwright & Co. 64%	113 150	Previous Buy Current Buy	Get Alert
Sep 24, 2024	BNTXBioNTech	$97.20	49.18%	Terence FlynnMorgan Stanley 72%	93 145	Previous Equal-Weight Current Overweight	Get Alert
Sep 19, 2024	BNTXBioNTech	$97.20	54.32%	Emmanuel PapadakisDeutsche Bank 46%	95 150	Previous Buy Current Buy	Get Alert
Sep 18, 2024	BNTXBioNTech	$97.20	34.77%	Eliana MerleUBS 60%	97 131	Previous Neutral Current Neutral	Get Alert
Sep 17, 2024	BNTXBioNTech	$97.20	54.32%	Akash TewariJefferies 49%	96 150	Previous Hold Current Buy	Get Alert
Sep 16, 2024	BNTXBioNTech	$97.20	28.6%	Jessica FyeJP Morgan 65%	91 125	Previous Underweight Current Neutral	Get Alert
Sep 16, 2024	BNTXBioNTech	$97.20	54.32%	Tazeen AhmadB of A Securities 57%	125 150	Previous Buy Current Buy	Get Alert
Sep 16, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	113 113	Previous Buy Current Buy	Get Alert
Sep 13, 2024	BNTXBioNTech	$97.20	-1.23%	Akash TewariJefferies 49%	90 96	Previous Hold Current Hold	Get Alert
Aug 27, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	113 113	Previous Buy Current Buy	Get Alert
Aug 19, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	113 113	Previous Buy Current Buy	Get Alert
Aug 15, 2024	BNTXBioNTech	$97.20	-6.38%	Jessica FyeJP Morgan 65%	91 94	Previous Underweight Current Underweight	Get Alert
Aug 7, 2024	BNTXBioNTech	$97.20	-2.26%	Emmanuel PapadakisDeutsche Bank 46%	95 95	Previous Hold Current Buy	Get Alert
Aug 6, 2024	BNTXBioNTech	$97.20	-12.55%	Yaron WerberTD Cowen 50%	85 98	Previous Hold Current Hold	Get Alert
Aug 1, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	113 113	Previous Buy Current Buy	Get Alert
Jun 26, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	113 113	Previous Buy Current Buy	Get Alert
Jun 12, 2024	BNTXBioNTech	$97.20	-3.29%	Jessica FyeJP Morgan 65%	90 94	Previous Underweight Current Underweight	Get Alert
Jun 10, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	113 113	Previous Buy Current Buy	Get Alert
Jun 4, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	113 113	Previous Buy Current Buy	Get Alert
Jun 3, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	113 113	Previous Buy Current Buy	Get Alert
May 30, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	113 113	Previous Buy Current Buy	Get Alert
May 28, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	113 113	Previous Buy Current Buy	Get Alert
May 24, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	113 113	Previous Buy Current Buy	Get Alert
May 14, 2024	BNTXBioNTech	$97.20	2.88%	Cory KasimovEvercore ISI Group 67%	100	Previous Initiates Current In-Line	Get Alert
May 8, 2024	BNTXBioNTech	$97.20	16.26%	Robert BurnsHC Wainwright & Co. 64%	107 113	Previous Buy Current Buy	Get Alert
May 7, 2024	BNTXBioNTech	$97.20	0.82%	Yaron WerberTD Cowen 50%	95 98	Previous Hold Current Hold	Get Alert
May 7, 2024	BNTXBioNTech	$97.20	25.51%	Etzer DaroutBMO Capital 68%	122 123	Previous Outperform Current Outperform	Get Alert
Apr 17, 2024	BNTXBioNTech	$97.20	10.08%	Robert BurnsHC Wainwright & Co. 64%	107 107	Previous Buy Current Buy	Get Alert
Mar 27, 2024	BNTXBioNTech	$97.20	3.91%	Eliana MerleUBS 60%	101 110	Previous Neutral Current Neutral	Get Alert
Mar 22, 2024	BNTXBioNTech	$97.20	-7.41%	Jessica FyeJP Morgan 65%	90 99	Previous Underweight Current Underweight	Get Alert
Mar 21, 2024	BNTXBioNTech	$97.20	75.93%	John NewmanCanaccord Genuity 41%	171 171	Previous Buy Current Buy	Get Alert
Mar 21, 2024	BNTXBioNTech	$97.20	26.54%	Etzer DaroutBMO Capital 68%	123 127	Previous Outperform Current Outperform	Get Alert
Feb 28, 2024	BNTXBioNTech	$97.20	2.88%	Chris ShibutaniGoldman Sachs 70%	100 113	Previous Neutral Current Neutral	Get Alert
Feb 23, 2024	BNTXBioNTech	$97.20	75.93%	John NewmanCanaccord Genuity 41%	171 171	Previous Buy Current Buy	Get Alert
Feb 23, 2024	BNTXBioNTech	$97.20	30.66%	Etzer DaroutBMO Capital 68%	127	Previous Initiates Current Outperform	Get Alert
Feb 21, 2024	BNTXBioNTech	$97.20	75.93%	John NewmanCanaccord Genuity 41%	171 171	Previous Buy Current Buy	Get Alert
Feb 20, 2024	BNTXBioNTech	$97.20	75.93%	John NewmanCanaccord Genuity 41%	168 171	Previous Buy Current Buy	Get Alert
Jan 23, 2024	BNTXBioNTech	$97.20	10.08%	Robert BurnsHC Wainwright & Co. 64%	107 133	Previous Buy Current Buy	Get Alert
Dec 1, 2023	BNTXBioNTech	$97.20	1.85%	Jessica FyeJP Morgan 65%	99 106	Previous Neutral Current Underweight	Get Alert

Recent Analyst Stock Rating News

PRO

William Blair Downgrades Alignment Healthcare to Market Perform

William Blair analyst Ryan Daniels downgrades Alignment Healthcare (NASDAQ:ALHC) from Outperform to Market Perform.

PRO

UBS Upgrades ArcelorMittal to Buy

UBS analyst Andrew Jones upgrades ArcelorMittal (NYSE:MT) from Neutral to Buy.

PRO

Citigroup Maintains Buy on Sunrun, Lowers Price Target to $14

Citigroup analyst Vikram Bagri maintains Sunrun (NASDAQ:RUN) with a Buy and lowers the price target from $16 to $14.

PRO

Citigroup Maintains Buy on Viper Energy, Lowers Price Target to $52

Citigroup analyst Paul Diamond maintains Viper Energy (NASDAQ:VNOM) with a Buy and lowers the price target from $57 to $52.

PRO

Citigroup Maintains Neutral on PepsiCo, Lowers Price Target to $135

Citigroup analyst Filippo Falorni maintains PepsiCo (NASDAQ:PEP) with a Neutral and lowers the price target from $142 to $135.

PRO

Citigroup Maintains Buy on Kodiak Gas Services, Lowers Price Target to $82

Citigroup analyst Douglas Irwin maintains Kodiak Gas Services (NYSE:KGS) with a Buy and lowers the price target from $86 to $82.

PRO

Citigroup Downgrades Pershing Square to Sell, Maintains Price Target to $45

Citigroup analyst Matthew Heimermann downgrades Pershing Square (NYSE:PS) from Neutral to Sell and maintains the price target from $45 to $45.

PRO

Citigroup Initiates Coverage On Fortune Brands with Buy Rating, Announces Price Target of $48

Citigroup analyst Anthony Pettinari initiates coverage on Fortune Brands (NYSE:FBIN) with a Buy rating and announces Price Target of $48.

PRO

Maxim Group Initiates Coverage On The RMR Group with Buy Rating, Announces Price Target of $26

Maxim Group analyst Michael Diana initiates coverage on The RMR Group (NASDAQ:RMR) with a Buy rating and announces Price Target of $26.

PRO

JP Morgan Maintains Neutral on Steel Dynamics, Lowers Price Target to $260

JP Morgan analyst Bill Peterson maintains Steel Dynamics (NASDAQ:STLD) with a Neutral and lowers the price target from $272 to $260.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

What Are Analyst Stock Ratings?

Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders.

Analysts arrive at stock ratings after they research companies’ public financial statements, communicate with executives and customers and interact with companies in other ways.

Most analysts issue ratings 4 times a year, usually at 3-month intervals.

How to Use Analyst Ratings

As an investor or trader, you want to be able to use analyst ratings effectively. Here are steps you can take to understand how to synthesize all the information analysts report about a particular company and how to apply it to your own trades.

Step 1: Check Ratings History

In the short term, look to see whether analysts suggest an initiation, upgrade or downgrade for a particular stock. Understand how the rating changed compared to the previous rating and whether a price target gets announced or changed.

Sometimes the rating stays the same and only the price target changes, which could cause the stock to move in either direction, depending on the significance of the change between the 2 price targets.

Step 2: Check for Other News

In the short term, check to see how the stock reacts to positive or negative news. This will be an indication of the company’s outlook because analyst ratings usually come out after the company announces news (it’ll typically be earnings news).

Step 3: Look at the Sector for News

Check to see if other stocks in the sector also received similar ratings. This could indicate micro news, which refers to when the whole sector or specific company trades in a specific way due to news outside of one company.

Step 4: Look at the Note

If available, look over the analyst note itself. The beginning of the note has the main information of the rating and price target. Investors should also take a look at the summary of the note, which you can find in the first couple pages and give you a concrete overview of the company. This can help you get an understanding of how analysts arrived at their thesis on the stock.

An example of an analyst note. Source: Needham

Step 5: Make a Decision

After reviewing the analyst ratings (and whether the analyst proposes a change or initiation) and find the reason for that note. Make a decision based on the analyst thesis on the company. This should give you guidance on how to make your thesis. Analyst ratings are a good indication of what professionals believe the company or sector will do, helping you get a better understanding of the companies you’re interested in.

Analyst Rating Accuracy

Analyst ratings are not set in stone and nobody knows indefinitely what a stock will do. Therefore, analyst ratings should be taken as an educated guess made by professionals who carefully study the specific company and sector in question. It's not a surprise that the accuracy of each rating can vary by each individual analyst and specific ratings on companies.

In other words, there’s no hard number or percentage on how accurate analyst ratings are because they are like educated guesses on what they think the stock will do based on their research, within that particular sector. In addition, each firm has so many analysts and so many different companies to review that you can compare ratings to glean what you believe is the truth.

Where Analyst Ratings Come From

Analyst ratings come from stock analysts. Analysts “go deep” on companies within a particular industry or sector. Some analysts employ a top-down approach (they start with an industry or sector and look for excellent companies within that industry or sector) and other stock analysts choose a bottom-up approach, which means they start with the company first and connect the dots within that company’s sector or industry. Analysts evaluate:

Financial statements
Economic fundamentals
Suppliers, customers and competitors
Management quality
Business model
Revenue
Expenses
Assets
Liabilities

While these evaluations are done using facts and figures that any investor can access, they come down to a conclusion the analyst must draw. While this isn’t an unqualified opinion, analysts will disagree because their interpretations of the data could vary.

Types of Stock Ratings

Stock ratings can range from simple “buy” and “sell” ratings to “equal weight” and “outperform” ratings. Here’s a quick overview of how analysts rate stocks.

Buy Rating

A “buy” rating indicates that an analyst is optimistic about a stock’s short-term or mid-term growth and recommends that traders purchase the stock. An analyst may even go so far as to indicate that a stock is a “strong buy.” At the same time, you may choose to swing trade the asset for a profit and come back later to start the process all over again.

Sell Rating

A “sell” rating means that an analyst believes the stock will trend downward in a particular time frame. Analysts might even refer to a security as a “strong sell.” Remember, though, you may want to swing trade and come back to this asset in the future even though you just chose to sell, just as you would under a “buy” rating.

Hold

A “hold” rating suggests that investors should not buy more of or sell the specified stock because they believe the stock should perform in a way that’s consistent with the market or will perform similarly to comparable companies within that particular sector. This is akin to the value investing approach that Warren Buffett uses, looking to gain long-term value from a single stock rather than flipping it because of a bad week. As many have said, it’s not a loss until you sell.

Underperform

An “underperform” rating means an analyst indicates that a stock is expected to perform below the market or sector average. And yes, while the underperform rating may not bode well for an asset in the next few weeks, it may not stay that way. Continue to carefully monitor your portfolio to ensure that an underperforming asset hasn’t turned itself around. As companies are faced with the Herculean task of pleasing shareholders, they will push to fix their underperforming stocks, meaning that a stock you wrote off could rise again.

Outperform

An “outperform” rating means that an analyst expects a stock to outperform the market or sector average. While the stock may look to outperform the market or a sector’s average, that doesn’t mean it will continue to soar forever. You must look at an outperform rating as what that asset will do in recent times, but it may not maintain that trajectory.

Equal-Weight

An equal weight rating means that an analyst believes that an individual stock's performance will tie to the average of all the stocks that an analyst covers in that particular sector. This type of rating helps investors get a true comparison of stocks to each other within a particular sector or industry. At the same time, equal-weight ratings could change at any time.

Price Target

A price target is an analyst’s projection of a stock’s future price. A price target is generally set up in a general trade or area where the asset might land. This means that the analyst could get close without hitting the figure on the head. Even so, the analyst wants to get close and better predict the movement of the marketplace and the asset.

Understanding Stock Ratings

Stock ratings are assessments of the investment potential of a particular stock. They are typically created by financial analysts who evaluate a company's financial performance, competitive positioning, and market outlook to provide guidance on the stock's expected future performance.

Ratings typically range from "buy" to "sell," with variations in between, such as "hold," "accumulate," or "neutral." A "buy" rating suggests that the stock is likely to perform well in the future, and investors should consider purchasing it. Conversely, a "sell" rating indicates that the stock is expected to underperform, and investors should consider selling it.

It's important to note that ratings are not guarantees of performance and should not be relied upon solely when making investment decisions. Ratings are just one factor to consider when evaluating a stock's potential, and investors should also conduct their own research and analysis to make informed decisions.

Another thing to keep in mind is that different analysts may have different opinions on a stock, so it's a good idea to consider multiple ratings before making an investment decision.

In addition to analyst ratings, investors can also consider other factors when evaluating a stock, such as its financial statements, management team, industry trends, and overall market conditions. By combining all of these factors, investors can make informed decisions about which stocks to buy or sell.

In summary, stock ratings are an important tool for investors to consider when evaluating a stock's potential, but they should not be the only factor used in investment decision-making. It's important to conduct your own research, consider multiple ratings, and take into account other factors before making an investment decision.

Should You Use Analyst Ratings to Inform Your Own Trades?

You can definitely use analyst ratings to inform your own trades and inform your own thesis but it’s a good idea to do your own research. However, analyst ratings are just one step in what should be a much larger investment strategy. Don’t fall in love with just one analyst. Compare notes. Look into how these ratings match with activity on the market and current events. Plus, remember that an analyst rating could easily be incorrect. No one is perfect, but these ratings are a good place to start.

Visit Benzinga News for more guidance on how to research companies and make decisions about research, trading and investing.

Compare Online Stock Brokers

Claim Exclusive Offers

Interactive Brokers Review
Good Fit For:
Active and Global Traders
VIEW PROS & CONS:
Securely through Interactive Brokers’ website
Plus500 Review
Good Fit For:
Leveraged Trading
VIEW PROS & CONS:
securely through Plus500 Yield's website
public.com Review
Good Fit For:
Trading Ideas
VIEW PROS & CONS:
securely through public.com's website
Robinhood Review
Good Fit For:
Commission-Free Mobile Trading
VIEW PROS & CONS:
securely through Robinhood's website
TradeZero Review
Good Fit For:
Active Short Sellers
VIEW PROS & CONS:
securely through TradeZero [SPONSORED]'s website